AnaptysBio Q2 collaboration revenue doubles

Reuters
Aug 07
AnaptysBio <a href="https://laohu8.com/S/QTWO">Q2</a> collaboration revenue doubles

Overview

  • AnaptysBio Q2 collaboration revenue more than doubles year-over-year

  • Net loss narrows to $38.6 mln from $46.7 mln in prior year

  • Co repurchased 9.3% of shares, reflecting confidence in financial position

Result Drivers

  • ROSNILIMAB DATA - Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis with strong safety and efficacy profile

  • ULCERATIVE COLITIS TRIAL - Completed enrollment for Phase 2 trial with top-line data expected in Q4 2025

  • PIPELINE ADVANCEMENT - Ongoing Phase 1 trials for ANB033 and ANB101, with plans for a Phase 1b cohort for ANB033 in celiac disease

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Collaboration Revenue

$22.26 mln

Q2 EPS

-$1.34

Q2 Net Income

-$38.63 mln

Q2 Income From Operations

-$26.17 mln

Q2 Operating Expenses

$48.43 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its August 5 closing price of $23.69

Press Release: ID:nGNX8G2DQs

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10